Standard antibiotics intravenously
Phase 2Small molecule
Standard antibiotics intravenously is one of 33 small molecule programs targeting Appendicitis. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
64 competitors in Appendicitis
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Flagyl
DDePuy Orthopaedics
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Piperacillin/tazobactam
PfizerApproved
Betadine
BBecton, Dickinson and Company
Approved
Merrem
BB. Braun Medical Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Marcaine
IInnocoll
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHerlev Hospital